Ciclopirox Olamine Exerts Tumor-Suppressor Effects via Topoisomerase II Alpha in Lung Adenocarcinoma
出版年份 2022 全文链接
标题
Ciclopirox Olamine Exerts Tumor-Suppressor Effects via Topoisomerase II Alpha in Lung Adenocarcinoma
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-02-18
DOI
10.3389/fonc.2022.791916
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues
- (2021) Áron Bartha et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy
- (2021) Firas Al-Zubaydi et al. Drug Delivery and Translational Research
- Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression
- (2020) Wook Jin Journal of Clinical Medicine
- Controversies and challenges in the histologic subtyping of lung adenocarcinoma
- (2020) Kelly J. Butnor Translational Lung Cancer Research
- Correction: Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer
- (2020) Jianjun Qi et al. Cell Death & Disease
- Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
- (2020) Y. Gong et al. Experimental Oncology
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment for Urothelial Cancers in Rats and Dogs
- (2019) Scott J Weir et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis
- (2019) Wenxia Ma et al. Cancer Cell International
- Current Diagnosis and Management of Small-Cell Lung Cancer
- (2019) Shuhang Wang et al. MAYO CLINIC PROCEEDINGS
- Gene Expression Signature-Based Approach Identifies Antifungal Drug Ciclopirox As a Novel Inhibitor of HMGA2 in Colorectal Cancer
- (2019) Yu-Min Huang et al. Biomolecules
- TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway
- (2018) Yao-fei Pei et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
- (2018) Katarzyna B. Hooks et al. HEPATOLOGY
- Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A
- (2018) Rui Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches
- (2018) Wei Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2018) Sanjay Popat NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma
- (2018) Song Xu et al. Thoracic Cancer
- DNA damage and apoptosis induced by a potent orally podophyllotoxin derivative in breast cancer
- (2018) Yajie Wang et al. Cell Communication and Signaling
- ROS and the DNA damage response in cancer
- (2018) Upadhyayula Sai Srinivas et al. Redox Biology
- Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
- (2017) Gregory M. Heestand et al. EUROPEAN JOURNAL OF CANCER
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK
- (2016) Hongyu Zhou et al. BIOCHEMICAL PHARMACOLOGY
- Repositioning the Old Fungicide Ciclopirox for New Medical Uses
- (2016) Tao Shen et al. CURRENT PHARMACEUTICAL DESIGN
- Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines
- (2016) Jianrong Wu et al. PLoS One
- Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases
- (2015) Kendra R. Vann et al. BIOCHEMISTRY
- Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection
- (2015) Matthias Kolberg et al. Molecular Oncology
- A Hypusine-eIF5A-PEAK1 Switch Regulates the Pathogenesis of Pancreatic Cancer
- (2014) K. Fujimura et al. CANCER RESEARCH
- Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies
- (2013) Mark D. Minden et al. AMERICAN JOURNAL OF HEMATOLOGY
- Blocking eIF5A Modification in Cervical Cancer Cells Alters the Expression of Cancer-Related Genes and Suppresses Cell Proliferation
- (2013) Elisabeth Mémin et al. CANCER RESEARCH
- Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity
- (2013) Siddhartha Sen et al. EXPERIMENTAL HEMATOLOGY
- Hemochromatosis Enhances Tumor Progression via Upregulation of Intracellular Iron in Head and Neck Cancer
- (2013) Michelle Lenarduzzi et al. PLoS One
- Target genes of Topoisomerase II regulate neuronal survival and are defined by their chromatin state
- (2012) V. K. Tiwari et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wnt Inhibitor Screen Reveals Iron Dependence of -Catenin Signaling in Cancers
- (2011) S. Song et al. CANCER RESEARCH
- The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway
- (2011) Y Luo et al. ONCOGENE
- ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
- (2010) J. C. Brase et al. CLINICAL CANCER RESEARCH
- The antitumor activity of the fungicide ciclopirox
- (2010) Hongyu Zhou et al. INTERNATIONAL JOURNAL OF CANCER
- Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells
- (2009) Y. Eberhard et al. BLOOD
- DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
- (2009) Yves Pommier CHEMICAL REVIEWS
- Targeting Wnt pathway in lymphoma and myeloma cells
- (2008) Matthias Schmidt et al. BRITISH JOURNAL OF HAEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started